Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Sima Ehsani

Oncologist, associate professor

University of Arizona

United States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (16)

Collaborators (5)

Jia Liu

The University of Sydney Faculty of Medicine and Health

Simak Ali

Imperial College London

UNITED KINGDOM

Alexandra S. Zimmer

UNITED STATES

Sagar Sardesai

Associate Professor

Ohio State University

UNITED STATES

Evanthia Roussos Torres

Assistant Professor

University of Southern California Norris Comprehensive Cancer Center

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sima Ehsani

Research Interests

Make your next move.

Explore related searches

Articles (16)

Collaborators (5)

Jia Liu

Simak Ali

Alexandra S. Zimmer

Sagar Sardesai

Evanthia Roussos Torres

Make your next move.

Sima Ehsani

Research Interests

Make your next move.

Explore related searches

Articles (16)

Collaborative model between breast surgery and genetic counseling reduces wait times and increases pretesting genetic counseling volume

Evaluation of Dronabinol to Decrease Opioid Use for Cancer-Induced Bone Pain

90O Dose optimization of zovegalisib, a novel PI3Kα inhibitor, in patients (pts) with PIK3CA-mutant (m) HR+/HER2− advanced breast cancer (BC): Results from the first-in-human (FIH) study to support the recommended phase III dose

A Nonrandomized Clinical Trial Investigating Keratinocyte Growth Factor‐Hair Serum for the Prevention of Chemotherapy‐Induced Alopecia

Abstract PD10-07: Efficacy of mutant-selective PI3Kα inhibitor RLY-2608 in combination with fulvestrant in patient (pt) subset populations, including pts with PIK3CA-mutant HR+/HER2- advanced breast cancer (BC) pre-treated with fulvestrant or other SERD

Abstract PS1-11-27: Evaluation of steroid hormone receptor expression and clinical outcomes in ER-positive breast cancer bone metastases

Abstract PS5-02-30: Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer

Abstract PS5-12-16: A Phase 2 Trial of (Z)-endoxifen + Goserelin as Neoadjuvant Treatment for Premenopausal Women with ER+, HER2-, Breast Cancer (EVANGELINE)

Circulating tumor (ct)DNA monitoring of ER+/HER2-high-risk breast cancer during adjuvant endocrine therapy

SAT-311 Investigating the Effects of Non-Estrogenic Reproductive Hormones on Human Estrogen Receptor-Positive Breast Cancer Bone Metastases in a Murine Model

Steroid receptor expression and overall survival in breast cancer patients with ER+ bone metastasis: A retrospective review.

Interrogating Steroid Hormone Signaling in a Murine Model of ER+ Human Breast Cancer Bone Metastases

Change in tumor microenvironment and PD-L1 expression with rucaparib treatment in triple-negative breast cancer.

Genomic and tumor microenvironment dynamics of brain metastases in breast cancer.

Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice

Abstract P4-04-02: Evaluation of Dronabinol to Decrease Opioid Use for Cancer- Induced Bone Pain

Collaborators (5)

Jia Liu

Simak Ali

Alexandra S. Zimmer

Sagar Sardesai

Evanthia Roussos Torres

Make your next move.